Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model | Zendy

Heijmen L. | Zendy; Voert E. G. W. | Zendy; Punt C. J. A. | Zendy; Heerschap A. | Zendy; Oyen W. J. G. | Zendy; Bussink J. | Zendy; Sweep C. G. J. | Zendy; Laverman P. | Zendy; Span P. N. | Zendy; GeusOei L. F. | Zendy; Boerman O. C. | Zendy; Laarhoven H. W. M. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model

Author(s) -

Heijmen L.,

Voert E. G. W.,

Punt C. J. A.,

Heerschap A.,

Oyen W. J. G.,

Bussink J.,

Sweep C. G. J.,

Laverman P.,

Span P. N.,

GeusOei L. F.,

Boerman O. C.,

Laarhoven H. W. M.

Publication year - 2014

Publication title -

contrast media & molecular imaging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.714

H-Index - 50

eISSN - 1555-4317

pISSN - 1555-4309

DOI - 10.1002/cmmi.1564

Subject(s) - bevacizumab , hypoxia (environmental) , glut1 , medicine , colorectal cancer , angiogenesis , tumor hypoxia , glucose transporter , immunohistochemistry , pathology , cancer research , nuclear medicine , chemistry , cancer , chemotherapy , radiation therapy , organic chemistry , oxygen , insulin

The purpose of this study was to assess the effect of bevacizumab on vasculature and hypoxia in a colorectal tumor model. Nude mice with subcutaneous LS174T tumors were treated with bevacizumab or saline. To assess tumor properties, separate groups of mice were imaged using 18 F‐Fluoromisonidazole (FMISO) and 18 F‐Fluorodeoxyglucose (FDG) positron emission tomography or magnetic resonance imaging before and 2, 6 and 10 days after the start of treatment. Tumors were harvested after imaging to determine hypoxia and vascular density immunohistochemically. The T 2 * time increased significantly less in the bevacizumab group. FMISO uptake increased more over time in the control group. Vessel density significantly decreased in the bevacizumab‐treated group. The Carbonic anhydrase 9 (CAIX) and glucose uptake transporter 1 (GLUT1) fractions were higher in bevacizumab‐treated tumors. However, the hypoxic fraction showed no significant difference. Bevacizumab led to shorter T 2 * times and higher GLUT1 and CAIX expression, suggesting an increase in hypoxia and a higher glycolytic rate. This could be a mechanism of resistance to bevacizumab. The increase in hypoxia, however, could not be demonstrated by pimonidazole/FMISO, possibly because distribution of these tracers is hampered by bevacizumab‐induced effects on vascular permeability and perfusion. Copyright © 2014 John Wiley & Sons, Ltd.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research